Bispecific antibody-mediated immunotherapy of the BCL1 lymphoma: Increased efficacy with multiple injections and CD28-induced costimulation

Blood

Volumn 87, Issue 10, 1996, Pages 4390-4398

  Demanet, Christian ^a   Brissinck, Jan ^a   De Jonge, Jan ^a   Thielemans, Kris ^a,b  

^a FREE UNIVERSITY OF BRUSSELS   (Belgium)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT LYMPHOCYTOTOXICITY; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; CROSS LINKING; DRUG EFFICACY; EFFECTOR CELL; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; KILLER CELL; LYMPHOMA; MEMORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

EID: 0029972715     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.10.4390.bloodjournal87104390     Document Type: Article

References (29)

1. Demanet C, Brissinck J, Van Mechelen M, Leo O, Thielemans K: Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-Idiotype × anti-CD3). J Immunol 147:1091, 1991
2. 1 lymphoma with bispecific antibodies. J Immunol 147:4019, 1991
3. 1 lymphoma. Cancer Res 54:2973, 1994
4. Jung G, Muller Eberhard HJ: An in vitro model for tumor immunotherapy with antibody heteroconjugates. Immunol Today 9:257, 1988
5. Jung O, Freimann U, von Marschall Z, Reisfeld RA, Wilmanns W: Target cell-induced T cell activation with bi-and trispecific antibody fragments. Eur J Immunol 21:2431, 1991
6. Bohlen H, Hopff T, Manzke O, Engert A, Kube D, Wickramanayake PD, Diehl V, Tesch H: Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 × CD19 bispecific antibodies in combination with bivalent CD28 antibodies. Blood 82:1803, 1993
7. Bohlen H, Manzke O, Patel B, Moldenhauer G, Dörken B, von Fliedner V, Diehl V, Tesch H: Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies. Cancer Res 53:4310, 1993
8. Renner C, Jung W, Sahin U, Denfeld R, Pohl C, Trümper L, Hartmann F, Diehl V, Van Lier R, Pfreundschuh M: Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. Science 264:833, 1994
9. 1, a murine model for chronic lymphocytic leukemia. Use of the surface immunoglobulin idiotype for the detection and treatment of tumor. Immunol Rev 48:81, 1979
10. 1). Role of an adherent cell in the suppression of primary in vitro antibody responses. J Immunol 126:1603, 1981
11. Weiner GJ, Kostelny SA, Hillstrom JR, Cole MS, Link BK, Wang SL, Tso JY: The role of T cell activation in anti-CD3 × antitumor bispecific antibody therapy. J Immunol 152:2385, 1994
12. Flamand V, Donckier V, Abramowicz D, Goldman M, Vandenabeele P, Urbain J, Moser M, Leo O: In vivo immunosuppression induced by a weakly mitogenic antibody to mouse CD3: Evidence that induction of long-lasting in vivo unresponsiveness requires TCR signaling. Cell Immunol 157:239, 1994
13. Bretscher P, Cohn M: A theory of self-nonself discrimination. Science 169:1042, 1970
14. Jenkins MK: The role of cell division in the induction of clonal anergy. Immunol Today 13:69, 1992
15. Schwartz RH: A cell culture model for T lymphocyte clonal anergy. Science 248:1349, 1990
16. Ellenhorn JD, Hirsch R, Schreiber H, Bluestone JA: In vivo administration of anti-CD3 prevents malignant progressor tumor growth. Science 242:569, 1988
17. Wolf H, Müller Y, Salmen S, Wilmanns W, Jung G: Induction of anergy in resting human T lymphocytes by immobilized anti-CD3 antibodies. Eur J Immunol 24:1410, 1994
18. June CH, Ledbetter JA, Linsley PS, Thompson CB: Role of the CD28 receptor in T-cell activation. Immunol Today 11:211, 1990
19. Harding FA, Mc Arthur JG, Gross JA, Raulet DH, Allison JP: CD28-mediated signalling costimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356:607, 1992
20. Linsley PS, Brady W, Grosmaire L, Aruffo A, Damle NK, Ledbetter JA: Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 173:721, 1991
21. Lindsten T, June CH, Ledbetter JA, Stella G, Thompson CB: Regulation of lymphokine messenger RNA stability by a surface mediated T cell activation pathway. Science 244:339, 1989
22. Croft M, Bradley LM, Swain SL: Naive versus memory CD4 T cell response to antigen. Memory cells are less dependent on accessory cell cosumulation and can respond to many antigen-presenting cell types including resting B cells. J Immunol 152:2675, 1994
23. Ehlers S, Smith KA: Differentiation of T cell lymphokine gene expression. The in vitro acquisition of T cell memory. J Exp Med 173:25, 1991
24. + T cells cannot be overcome by CD28 costimulation. Eur J Immunol 24:1956, 1994
25. + T cells require a costimulatory signal mediated through the LFA-1/ICAM-1 pathway. J Immunol 148:1993, 1992
26. + T cells. ICAM-1 or B7-1 can costimulate naive CD4 T cell activation but both are required for optimum response. J Immunol 155:45, 1995
27. Azuma M, Cayabyab M, Buck D, Phillips JH, Lanier LL: CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes. J Exp Med 175:353, 1992
28. Azuma M, Cayabyab M, Phillips JH, Lanier LL: Requirements for CD28-dependent T cell-mediated cytotoxicity. J Immunol 150:2091, 1993
29. Renner C, Jung W, Sahin U, Van Lier R, Pfreundschuh M: The role of lymphocyte subsets and adhesion molecules in T cell-dependent cytotoxicity mediated by CD3 and CD28 bispecific monoclonal antibodies. Eur J Immunol 25:2027, 1995